Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression

ABSTRACT: Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression

PROVIDER: PRJNA1119415 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29262500_1.fastq.gz	Fastqsanger.gz
	SRR29262500_2.fastq.gz	Fastqsanger.gz
	SRR29262501_1.fastq.gz	Fastqsanger.gz
	SRR29262501_2.fastq.gz	Fastqsanger.gz
	SRR29262502_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression

Project description:More than 90% of hepatocellular carcinoma (HCC) cases develop in the presence of fibrosis or cirrhosis, making the tumor microenvironment (TME) of HCC distinctive due to the intricate interplay between cancer-associated fibroblasts (CAFs) and cancer stem cells (CSCs), which collectively regulate HCC progression. However, the mechanisms through which CSCs orchestrate the dynamics of the tumor stroma during HCC development remain elusive. Our study unveils a significant upregulation of Sema3C in fibrotic liver, HCC tissues, peripheral blood of HCC patients, as well as sorafenib-resistant tissues and cells, with its overexpression correlating with the acquisition of stemness properties in HCC. We further identify NRP1 and ITGB1 as pivotal functional receptors of Sema3C, activating downstream AKT/Gli1/c-Myc signaling pathways to bolster HCC self-renewal and tumor initiation. Additionally, HCC cells-derived Sema3C facilitated extracellular matrix (ECM) contraction and collagen deposition in vivo, while also promoting the proliferation and activation of hepatic stellate cells (HSCs). Mechanistically, Sema3C interacted with NRP1 and ITGB1 in HSCs, activating downstream NF-kB signaling, thereby stimulating the release of IL-6 and upregulating HMGCR expression, consequently enhancing cholesterol synthesis in HSCs. Furthermore, CAF-secreted TGF-β1 activates AP1 signaling to augment Sema3C expression in HCC cells, establishing a positive feedback loop that accelerates HCC progression. Notably, blockade of Sema3C effectively inhibits tumor growth and sensitizes HCC cells to sorafenib in vivo. In sum, our findings spotlight Sema3C as a novel biomarker facilitating the crosstalk between CSCs and stroma during hepatocarcinogenesis, thereby offering a promising avenue for enhancing treatment efficacy and overcoming drug resistance in HCC.

2024-07-10 | GSE268894 | GEO

Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression

Project description:The proteins binding Sema3C and NRP1 in hepatocellular carcinoma cells were analyzed by mass spectrometry

2024-06-03 | PXD052807 |

MoS2 Reshapes the Tumor Microenvironment to Promote Tumor Cell Ferroptosis

Project description:MoS2 Reshapes the Tumor Microenvironment to Promote Tumor Cell Ferroptosis

| PRJNA1055446 | ENA

Salmonella sp. 3C strain:3C

Project description:Salmonella sp. 3C strain:3C Genome sequencing

| PRJNA882226 | ENA

MoS2 Reshapes the Tumor Microenvironment to Promote Tumor Cell Ferroptosis

Project description:MoS2 has found application in various biomedical fields, such as bioimaging and drug delivery. Nonetheless, utilizing MoS2 for anti-tumor therapy remains challenging, especially tumor immunotherapy. Macrophages, pivotal constituents of the tumor microenvironment, play a crucial role in driving tumor progression and chemoresistance. Modulating macrophages to reshape this microenvironment stands as a promising avenue for effective tumor treatment. In this study, we unveil a mechanism by which MoS2 induces the metamorphosis of macrophages from an M0 to an M1 phenotype, thus altering the tumor microenvironment. This transformation triggers pathways associated with inflammation within M1-type macrophages, leading to an upsurge in the expression of inflammatory molecules like IL1β. Macrophages activated by MoS2 exhibit a propensity to impede tumor cell proliferation. Through comprehensive RNA-sequencing analysis, we noted that MoS2 induces a greater enrichment of differentially expressed genes in the cytokine release pathway within macrophages. The excessive secretion of IL1β by MoS2-activated macrophages emerges as a pivotal catalyst, heightening ROS levels and decreasing GSH levels within tumor cells, ultimately culminating in ferroptosis. Therefore, we suggest MoS2 effectively reshapes the tumor microenvironment by steering macrophages toward releasing inflammatory molecules. The MoS2-triggered activation of macrophages, inducing the secretion of IL1β, emerges as a potent trigger for ferroptosis within tumor cells. Consequently, MoS2 holds substantial promise as an efficacious strategy for anti-tumor immunotherapy, achieved through the polarization of macrophages.

2023-12-31 | GSE251769 | GEO

Scytalidium sp. 3C strain:3C

Project description:Scytalidium sp. 3C strain:3C Genome sequencing and assembly

| PRJNA243259 | ENA

Verrucomicrobium sp. 3C strain:3C

Project description:Verrucomicrobium sp. 3C strain:3C Genome sequencing and assembly

| PRJNA165235 | ENA

Gene expression profiles of Semaphorin 3G stimulated macrophages [RNA-seq]

Project description:Although Semaphorin 3G has some roles in the development of vessels, the roles in immune system are not characterized. We aimed to study how Semaphorin 3G affects the function of macrophages.

2022-05-17 | GSE176438 | GEO

Human hepatocellular carcinoma samples proteomic analysis

Project description:Lysine metabolism reprogramming reshapes the immune microenvironment and induces immunotherapy tolerance in liver cancer

2024-06-17 | PXD053184 |

In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases

Project description:In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases

| PRJNA913952 | ENA